 Home > Active Ingredient News > Blood System > AJH: Patients with myeloproliferative tumors treated with Ruxotinib have an impaired response to the first SARS-CoV-2 vaccination

AJH: Patients with myeloproliferative tumors treated with Ruxotinib have an impaired response to the first SARS-CoV-2 vaccination

 Last Update: 2022-01-08
 Source: Internet
 Author: User

Tags

dead cells 2

use methylene blue

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Covid-19 is a disease caused by the pandemic SARS-CoV-2 infection , which has had a significant impact on patients with blood system diseases

A research team prospectively evaluated the serological response of 30 consecutive patients with PV, ET, and MF after the first injection of SARS-CoV-2 mRNA vaccine

Figure 1: 18 MPN patients (black diamonds) treated with Ruxotinib, 12 MPN patients (red diamonds) not treated with Rusotinib, 14 healthy people (A) anti-Spike IgG, (B ) Serum level control (blue diamond) of anti-RBD IgG, (C) neutralizing antibody, before the first (T0) or second (T1) vaccine administration

Figure 1: 18 MPN patients (black diamonds) treated with Rusotinib, 12 MPN patients (red diamonds) not treated with Rusotinib, 14 healthy people (A) anti-Spike IgG, (B ) Serum level control (blue diamond) of anti-RBD IgG, (C) neutralizing antibody, before the first (T0) or second (T1) vaccine administration

Figure1 shows the level of individual anti-SARS-CoV-2 antibodies at T0 and T1

p p p p 1(D)-(F)

In summary, due to the limited number of subjects included, these findings provide a strong and urgent argument for the impaired early response of patients receiving ruxolitinib to the SARS-CoV-2 vaccine

Patients receiving ruxolitinib have impaired early response to SARS-CoV-2 vaccine

It is important to resolve whether the response mediated by T cells and other bone marrow cells is also impaired by Ruxotinib treatment, as they play a key role in SARS-CoV-2 infection

Whether the response mediated by T cells and other bone marrow cells is also impaired by Ruxortinib treatment, because they play a key role in SARS-CoV-2 infection to prevent the initiation of Ruxortinib in patients not receiving Ruxortinib Tinib treatment may be prudent to delay the completion of vaccination, unless it is urgently needed
.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

SULODEXIDE 99% Almost White Powder Dideu-01112 Dideu

CAS No.: 57821-29-1

Pharmacy Grade

$61.76/G EXW

Heparin sodium 9041-08-1 vials safe delivery

CAS No.: 9041-08-1

Pharmacy Grade

$1/G EXW

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.